TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03725306

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Librata
Description: Hyperthermic endomyometrial treatment via Librata catheter and balloon device
Study: NCT01659827

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Marcaine
Description: Injection of 2cc of Marcaine

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Marcaine
Description: Injection of 2cc of Marcaine

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Marcaine
Description: Injection of 2cc of Marcaine

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 0.5cc AmnioFix
Description: Injection of 0.5cc of AmnioFix Injectable
Study: NCT03397264

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: OPT-302
Description: Intravitreal Injection

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: OPT-302
Description: Intravitreal Injection

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: OPT-302
Description: Intravitreal Injection

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: OPT-302
Description: Intravitreal Injection

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Sham intravitreal injection
Description: Sham (mock) intravitreal injection
Study: NCT01615731

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mifepristone
Description: 200mg Mifepristone orally

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Hygroscopic cervical dilators
Description: Dilapan-S osmostic cervical dilators inserted through the internal os

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Hygroscopic cervical dilators
Description: Dilapan-S osmostic cervical dilators inserted through the internal os

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Misoprostol
Description: 400mcg buccal misoprostol 90 minutes pre-op
Study: NCT02209779

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Study: NCT00003833

Intervention type: GENETIC
Intervention: DNA stability analysis

Intervention type: GENETIC
Intervention: gene mapping
Study: NCT04650100

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: ultrasound-guided PENG bloc realized before surgery
Description: ultrasound-guided PENG block realized before surgery. The PENG block, described by Giron-Arebgi is made in the supine position. The ultrasound probe used is a 5 MHz high frequency linear probe placed parallel to the line delimited by the anterior-inferior iliac spine (lateral) and the pubis (medial). The needle used is an 80 mm, 22G, needle inserted in the ultrasound plane. The slow and fractioned injection of 20 ml of Ropivacaine 4.75 mg/ml is performed in the fascia between the psoas tendon and the iliopubic eminence under ultrasound guidance.
Study: NCT04217668

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Isosorbide Mononitrate 60 MG
Description: 1 tablet Isosorbide Mononitrate 60 mg administrated orally.
Study: NCT03432000

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Performances of patients and controls on temporal task
Description: To carry out this work, we will rely on an experimental paradigm (derived from Michotte's paradigm) which makes it possible to explore the links between temporal sequencing and perception of causality, validated in the normal subject. subjective consequences of these alterations will be explored using a phenomenological-inspired clinical scale (EAWE time-scale items)

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Performances of patients and controls on temporal task
Description: To carry out this work, we will rely on an experimental paradigm (derived from Michotte's paradigm) which makes it possible to explore the links between temporal sequencing and perception of causality, validated in the normal subject. subjective consequences of these alterations will be explored using a phenomenological-inspired clinical scale (EAWE time-scale items)
Study: NCT01488578

Intervention type: DRUG
Intervention: Tolterodine tartrate
Description: Detrusitol Capsule 2mg and 4mg, depending on the Investigator prescription.Frequency and duration are according to Package Insert as follows.
Study: NCT05547893

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: simulation
Description: participating a simulated clinical ethical situation with simulation patients
Study: NCT04221555

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel, Oxaliplatin, S-1 and Durvalumab
Description: 1. Neoadjuvant treatment Durvalumab 1120 mg IV on day (D) 1, Docetaxel 50 mg/m2 intravenously (IV) on D1, oxaliplatin 100 mg/m2 IV on D1, S-1 40 mg/m2 bid orally on D1-14, will be administered every three weeks for three cycles.~2. Surgery~3. Adjuvant treatment After 4-6 weeks from surgery, S-1 40 mg/m2 bid orally on D1-28 plus durvalumab 1120 mg on D1 and D22 will be administered every 6 weeks for 12 months as an adjuvant treatment.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Durvalumab and Tremelimumab
Description: 1. Neoadjuvant treatment Durvalumab 1500 mg IV and tremelimumab 75 mg IV on D1 will be administered every four weeks for three cycles.~2. Surgery~3. Adjuvant treatment After 4-6 weeks from surgery, durvalumab 1500 mg on D1 will be administered every 4 weeks for 12 months as an adjuvant treatment.
Study: NCT04277195

Intervention type: DIAGNOSTIC_TEST
Intervention: SPAG5 Assay
Description: Testing for SPAG5 expression in the tumour.

Intervention type: DIAGNOSTIC_TEST
Intervention: SPAG5 Assay
Description: Testing for SPAG5 expression in the tumour.

Intervention type: DIAGNOSTIC_TEST
Intervention: SPAG5 Assay
Description: Testing for SPAG5 expression in the tumour.

Intervention type: DIAGNOSTIC_TEST
Intervention: SPAG5 Assay
Description: Testing for SPAG5 expression in the tumour.
Study: NCT00708929

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Squatting
Description: Squatting for 6 minutes

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Squatting
Description: Squatting for 6 minutes
Study: NCT02961452

Intervention type: OTHER
Intervention: Cross reaction detection
Study: NCT03651661

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: human insulin
Description: human insulin administered as nasal spray

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: placebo administered as nasal spray

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Pupillography
Description: Autonomic tone will be adressed by pupillography using the F2D2 (Amtech Germany) device.

Intervention type: DIAGNOSTIC_TEST
Group type: PLACEBO_COMPARATOR
Intervention: Pupillography
Description: Autonomic tone will be adressed by pupillography using the F2D2 (Amtech Germany) device.
Study: NCT01806883

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: WII Rehabilitation
Description: 30 patients will receive Wii rehabilitation of 15 minutes (tennis, boxing and golf), in comparison with 10 healthy subjects.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Traditional rehabilitation
Description: 30 patients will receive the traditional rehabilitation.
Study: NCT02831530

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Abemaciclib
Study: NCT01733719

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: ER plus RFA

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: ER plus APC
Description: 2 litres/minute, 70 watts
Study: NCT04624191

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Saturation at home
Description: Clinical benefit of taking saturation at home in interstitial lung disease
Study: NCT00681408

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Omega 3 Fish Oil supplements
Description: Subjects in this arm will receive 3 grams daily Omega 3 fish oil supplements

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Fish oil placebo pills
Study: NCT00254397

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Leuprolide
Description: A 3-month 11.25 mg sustained-release formulation will be administrated intramuscularly at time 0, and approximately 12 weeks (2 injections).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Leuprolide
Description: A 3-month 11.25 mg sustained-release formulation will be administrated intramuscularly at time 0, and approximately 12 weeks (2 injections).

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GP100: 209-217(210M) Peptide
Description: 1.0 ml subcutaneous injection in extremities.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GP100: 209-217(210M) Peptide
Description: 1.0 ml subcutaneous injection in extremities.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GP100: 209-217(210M) Peptide
Description: 1.0 ml subcutaneous injection in extremities.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GP100: 209-217(210M) Peptide
Description: 1.0 ml subcutaneous injection in extremities.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MAGE-3 Peptide
Description: 1.0 ml subcutaneous injection in extremities.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MAGE-3 Peptide
Description: 1.0 ml subcutaneous injection in extremities.
Study: NCT04780737

Intervention type: PROCEDURE
Intervention: Cholecystectomy
Description: Laparoscopic or laparotomic cholecystectomy

Intervention type: PROCEDURE
Intervention: Cholecystectomy
Description: Laparoscopic or laparotomic cholecystectomy
Study: NCT01893502

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Telephone counselling from Quitline

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Telephone counselling from Quitline
Study: NCT01403883

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Standard Care
Description: Psychological \& enterostomal therapy clinics on demand only

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Optimal care (Psychological and enterostomal therapy clinics)
Description: Psychological clinics at D-45, D0, D45, D60, D90 enterostomal therapy clinics at D-45, D0, D45, D60
Study: NCT02630745

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Immediate periodontal surgery
Description: Treatment involves immediate surgical periodontal therapy in form of open flap debridement after non surgical endodontic treatment and obturation with gutta-percha and zinc oxide eugenol (ZOE) sealer. in concurrent endodontic periodontal lesions with communication .

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Delayed periodontal surgery
Description: Treatment involves surgical periodontal therapy after 3 months of non surgical endodontic treatment and obturation with gutta-percha and zinc oxide eugenol (ZOE) sealer. in the form of open flap debridement in concurrent endodontic periodontal lesions with communication .
Study: NCT04033133

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: tDCS
Description: Subjects will get tDCS at intensities of 0, 1, 2, 3, and 4 mA.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: tDCS
Description: Subjects will get tDCS at intensities of 0, 1, 2, 3, and 4 mA.
Study: NCT02272348

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Training course to functional insulin therapy
Description: Carbohydrate counting, carbohydrate/insulin ratio, sensitivity to insulin factor

Intervention type: OTHER
Group type: OTHER
Intervention: Usual diabetes management.
Study: NCT01698320

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo MDPI
Description: Placebo MDPI (multi-dose dry powder inhaler) to match the active intervention.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Albuterol MDPI
Description: Albuterol MDPI (multi-dose dry powder inhaler or Spiromax®) 90 mcg/inhalation.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Albuterol MDPI
Description: Albuterol MDPI (multi-dose dry powder inhaler or Spiromax®) 90 mcg/inhalation.
Study: NCT04028583

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: PIM-Check
Description: In the PIM-Check group, a medication review will be conducted using PIM-Check within 72 hours of patient's admittance to the unit. The physician will decide whether to accept these recommendations or not and implement prescribing changes if agreed.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: STOPP/START
Description: In the STOPP/START group, medication lists will be analyzed within 72 hours of patient's admittance and optimized according to STOPP/START criteria. The second physician will decide whether to accept these recommendations or not and implement prescribing changes if agreed.
Study: NCT04405206

Intervention type: DRUG
Intervention: Oxaliplatin
Description: OXA 130mg/m2

Intervention type: DRUG
Intervention: Oxaliplatin
Description: OXA 130mg/m2

Intervention type: DRUG
Intervention: Oxaliplatin
Description: OXA 130mg/m2

Intervention type: DRUG
Intervention: Capecitabine
Description: Cape 1000mg/m2

Intervention type: DRUG
Intervention: Capecitabine
Description: Cape 1000mg/m2

Intervention type: DRUG
Intervention: Capecitabine
Description: Cape 1000mg/m2

Intervention type: RADIATION
Intervention: intensity modulated radiotherapy
Description: IMRT 50.4Gy/22f

Intervention type: RADIATION
Intervention: intensity modulated radiotherapy
Description: IMRT 50.4Gy/22f

Intervention type: RADIATION
Intervention: intensity modulated radiotherapy
Description: IMRT 50.4Gy/22f

Intervention type: PROCEDURE
Intervention: DRE-Endoscopy-MRI-CEA
Description: examination process in follow up
Study: NCT01659827

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 1.25cc AmnioFix
Description: Injection of 1.25cc of AmnioFix Injectable

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Saline
Description: Injection of 1.25cc of Saline
Study: NCT00975182

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GDC-0941
Description: Oral repeating dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: erlotinib HCl
Description: Oral repeating dose
Study: NCT01283464

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Retinol
Description: 1.0% cream

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tretinoin
Description: 0.02% cream
Study: NCT00553839

Intervention type: DRUG
Group type: OTHER
Intervention: ketamine hydrochloride
Description: Open label pharmacokinetic study to be conducted in infants and children presenting for medical procedures (eg., surgery or cardiac catheterization). After the start of the procedure, a 0.5 cc preload blood sample (T0) will be drawn from an IV line. Then a 2 mg/kg IV bolus of Ketamine will be administered over 5 minutes. Timed 0.5 ml blood samples will be drawn at the following intervals: 5, 10, 15, 20, 30, 45, 60, 120, 180, 240, 300, 360 and 720 minutes after bolus.
Study: NCT02045069

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 2 days Ivermectin
Description: 200-400 µg/kg once daily for 2 days and placebo once daily at D3

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 3 days Ivermectin
Description: 200 -400 µg/kg once daily for 3 days

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo once daily for 3 days
Study: NCT01764360

Intervention type: OTHER
Group type: OTHER
Intervention: KS structured clinical care training
Description: Eight primary care sites in Zimbabwe will receive structured training for diagnosis and treatment of Kaposi sarcoma (KS)
Study: NCT01422564

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Metal on Metal Hip System
Description: Total hip arthroplasty with a metal on metal component system

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Highly Cross Linked Polyethylene cup System
Description: Total hip arthroplasty with Highly Cross Linked Polyethylene cup System
Study: NCT03299660

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Avelumab
Description: Avelumab 10 mg/Kg every 2 weeks for 4 cycles post LCCRT

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 5 Fluorouracil
Description: 5FU continuous infusion 225mg/m2/day during radiotherapy

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capecitabine Pill
Description: Can be administered in place of 5FU infusion. Dose = 825 mg/m2 twice a day on each day of radiotherapy

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiotherapy
Description: 50.4 Gy in 28 fractions delivered over 5.5 weeks as 5 fractions/week

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Surgical Resection
Description: Surgical resection of tumour mass post radiotherapy and chemotherapy
Study: NCT02606916

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: SMART
Description: Once-daily simultaneous modulated accelerated radiotherapy(64Gy/30f )

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DDP
Description: DDP(25 mg/m2.qw) for six weeks.
Study: NCT02606916

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: S-1
Description: S-1(40 mg/m2.Bid .po) on D1-14，D22-35 during radiotherapy
Study: NCT01099150

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Dark chocolate enriched in flavan-3-ols and procyanidins
Description: Acute consumption (within 15 minutes) of 60 g of chocolate containing \~900 mg of total flavan-3-ols and procyanidins.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Standard dark chocolate
Description: Acute consumption (within 15 minutes) of 60 g of chocolate containing \~400 mg total flavan-3-ols and procyanidins.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: White chocolate
Description: Acute consumption (within 15 minutes) of 60 g of white chocolate containing no flavan-3-ols and procyanidins.
Study: NCT02351609

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Intervention
Description: Intervention patients will be introduced to the patient navigator either in person or by telephone. The intervention patients will receive navigation from one of two trained navigators, based centrally in the Section of General Internal Medicine. The purpose of the patient navigation interactions is to 1) connect patients to existing yet underutilized smoking cessation resources and 2) increase patient commitment to follow through with existing treatment services.~Financial incentives: $250 for biochemically confirmed abstinence within six months after study enrollment, and $500 for biochemically confirmed abstinence for an additional six months after the initial cessation.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Enhanced Traditional Care control
Description: List of smoking cessation resources and educational brochure.
Study: NCT04430556

Intervention type: DRUG
Group type: OTHER
Intervention: Sertraline
Description: Sertraline will be started in all patients, unless it is contraindicated, in this case, Escitalopram will be indicated.
Study: NCT04722068

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Kinetics test
Description: Subjects will participate in two study visits to evaluate lipoprotein kinetics before and after administration of evinacumab.
Study: NCT04145180

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Manual therapy
Description: 40 minutes of physiotherapy, based on manual therapy sessions over 6 weeks. Three times a week.
Study: NCT00637312

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Cervical Artificial Disc (Advent™ Cervical Disc)
Description: Advent™ Cervical Disc

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Hallmark™ Anterior Cervical Plate System
Description: Hallmark™ Anterior Cervical Plate System with AlloQuent Structural Allograft (corticocancellous allograft bone)
Study: NCT03357523

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Omnilux new-U (Red LED)
Description: The left wrist (including area of radial artery) will be illuminated with the Omnilux new-U (Red LED) light source, while the right wrist will not be illuminated

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Omnilux new-U (Near infrared LED)
Description: The left wrist (including area of radial artery) will be illuminated with the Omnilux new-U (Near infrared LED) light source, while the right wrist will not be illuminated

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: RESPeRATE
Description: The subjects will be guided by a digital metronome to breath at 15, 10, and 6 breaths/min for 2 minutes each using the metronome function of the device RESPeRATE (InterCure, Israel) that guides breathing using musical tones played at selectable rhythm

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: RESPeRATE
Description: The subjects will be guided by a digital metronome to breath at 15, 10, and 6 breaths/min for 2 minutes each using the metronome function of the device RESPeRATE (InterCure, Israel) that guides breathing using musical tones played at selectable rhythm

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Heating bag
Description: Applying a standard 10X13 \[cm\] heating bag on the surface of the hand at 43-45 degree Celsius for 10 seconds

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Heating bag
Description: Applying a standard 10X13 \[cm\] heating bag on the surface of the hand at 43-45 degree Celsius for 10 seconds
Study: NCT01493674

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: folic acid
Description: two 5-mg tablets of folic acid
Study: NCT02146014

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Transcranial Direct Current Stimulation (tDCS) is a procedure that uses a small battery-driven unit to deliver weak electrical currents (1-2 mA) through the intact scalp. The procedure is painless and is thought to modulate the excitability of the underlying cerebral tissue for hours or days after sessions.~In the placebo group the current will be off.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transcranial Direct Current Stimulation
Description: Transcranial Direct Current Stimulation (tDCS) is a procedure that uses a small battery-driven unit to deliver weak electrical currents (1-2 mA) through the intact scalp. The procedure is painless and is thought to modulate the excitability of the underlying cerebral tissue for hours or days after sessions.
Study: NCT00925951

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Wet Cupping
Description: Wet cupping (Seongho trade \& company, Korea) will be practiced at two selected points (among the 6 acupoints, left or right BL23, BL24, BL25)

Intervention type: DRUG
Group type: NO_INTERVENTION
Intervention: Acetaminophen
Description: Acetaminophen 500 mg tablets will be offered to both of the wet cupping group and waiting group for relieving severe pain.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Acetaminophen
Description: Acetaminophen 500 mg tablets will be offered to both of the wet cupping group and waiting group for relieving severe pain.